Shares of Johnson & Johnson (JNJ) Sees Large Inflow of Net Money Flow

Johnson & Johnson (JNJ) witnessed a selling pressure and the shares last traded with a loss of -0.02 points or -0.02% at $113.23. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $30.13 million with an inflow of $189.8 million in upticks and an outflow of $159.67 million in downticks. Using the data, the up/down ratio is found to be 1.19. The share price has recorded -0.13% on a weekly basis.A block trade of $81.74 million in uptick and $47.31 million in downtick was also observed, resulting in an up/down ratio of 1.73. The net money flow of the block trade stood at a $34.43, signaling heavy buying.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of Johnson & Johnson appreciated by 0.38% during the last five trading days but lost 1.72% on a 4-week basis. Johnson & Johnson has dropped 1.7% during the last 3-month period . Year-to-Date the stock performance stands at -1.72%. Johnson & Johnson (NYSE:JNJ) witnessed a decline in the market cap on Wednesday as its shares dropped 0.02% or 0.02 points. After the session commenced at $112.48, the stock reached the higher end at $113.32 while it hit a low of $112.47. With the volume soaring to 7,082,322 shares, the last trade was called at $113.23. The company has a 52-week high of $126.07. The company has a market cap of $308,046 million and there are 2,720,531,700 shares in outstanding. The 52-week low of the share price is $99.78.

Company has reported several Insider transactions to the SEC, on Jul 28, 2016, Dominic J Caruso (Exec VP, Finance; CFO) sold 41,146 shares at 125.01 per share price.On Jul 25, 2016, Ronald A Kapusta (Controller, CAO) sold 2,935 shares at 125.01 per share price.On Jun 9, 2016, Gary J Pruden (Exec VP, WW Chair, Med Devices) sold 9,735 shares at 116.03 per share price.

Johnson & Johnson Last issued its quarterly earnings results on Jan 24, 2017. The company reported $1.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $1.56. The company had revenue of $18106.00 million for the quarter, compared to analysts expectations of $18259.82 million. The companys revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Johnson & Johnson was Downgraded by Wells Fargo to Market Perform on Jan 26, 2017. Johnson & Johnson was Reiterated by RBC Capital Mkts on Jan 25, 2017 to Outperform, Lowers Price Target to $ 128 from a previous price target of $133 .

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and womens health fields, nutritional and over-the-counter pharmaceutical products. The companys Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and womens health products. Johnson & Johnson is based in New Brunswick, New Jersey.


Share this post

Leave a Reply